Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: TokyoMex who wrote (482)	6/11/1998 10:06:00 PM
From: Emec	Read Replies (1) \| Respond to of 1510

Yes. Wonder how many shorts there will be as of may 12, 1998?

To: TokyoMex who wrote (482)	6/11/1998 10:41:00 PM
From: Emec	Respond to of 1510

ROFLMAO. This is out at 8:50? Didn't Reuters see the freaking news!! Thursday June 11, 8:50 pm Eastern Time U.S. OPTIONS/Immune Response vols surge CHICAGO, June 11 (Reuters) - Implied volatility on Immune Response Corp. options spiked on Thursday as the stock rallied amid a broad-based stock market decline. The company, which held its annual meeting this morning, said it did not know what was driving the stock or options, adding that it made no important announcements at the meeting. Yet implied volatility for July at-the-money options rose as high as 130 percent, up sharply from its average of around 75 to 80 percent. The underlying stock advanced 1-15/16 to 13-11/16, even as the Nasdaq shed 1.3 percent. ''It can't sustain these kinds of volatility levels for long,'' said Jon Najarian, president of Mercury Trading. He noted sizable open interest in the soon-to-expire June 12-1/2 calls, which drew the most volume today, registering more than 950 contracts. ''It could just be a short squeeze of those who sold those options last week, and not just speculators betting on a price rise,'' Najarian said. The June 15 calls also saw good volume, with more than 500 contracts changing hands. A market maker in the options noted good two-way business. ''We've seen buy writers, call sellers -- it has been spread pretty evenly,'' he said. Implied volatility and volume had risen steadily earlier this week as an independent group, the Data Safety Monitoring Board, told Immune Response that the company should continue Phase III trials of its HIV drug. The three-year trials for the drug, the furthest along in its product pipeline, were scheduled to be completed in March 1999, said company spokeswoman Deb Altman. In other trading, implied volatility on Triton Oil (OIL - news) options advanced up to around 60 percent from an average of about 44 percent over the past few months as the stock, pressured by the decline in crude oil prices, lost 1-9/16 to close at 35-1/2. The S&P 100 tumbled 7.97 points to 531.83 as worries about turmoil in Asia deepened. Michael Schwartz, a managing director of CIBC Oppenheimer, said unwinding of options positions ahead of the expiration of June contracts next week exacerbated the decline. "That probably will continue into next week," he said. More Quotes and News: Immune Response Corp (Nasdaq:IMNR - news) Triton Energy Corp (NYSE:OIL - news) Related News Categories: options, US Market News

To: TokyoMex who wrote (482)	6/11/1998 11:58:00 PM
From: Emec	Respond to of 1510

Looks better all the time (UPDATE) Immune Response, Agouron To Collaborate On HIV Drug; Investors Cheer Dow Jones Online News, Thursday, June 11, 1998 at 21:20 LA JOLLA, Calif. -(Dow Jones)- Agouron Pharmaceuticals Inc. and Immune Response Corp. Thursday announced an agreement to work together on the development and commercialization of Immune Response's Remune therapy for HIV. The announcement gave Immune Response's stock a sharp boost, and prompted positive comments from analysts. Agouron (AGPH) said it will have exclusive rights to market Remune in North America, Europe and certain other countries, while Immune Response will manufacture commercial supplies of the drug to be used in the treatment of the virus that causes AIDS. Immune Response shares (IMNR) closed up $1.937, or 17%, to $13.687. Nasdaq volume totaled 1 million shares, compared with average daily volume of 290,500 shares. "It's definitely fabulous news," said Gruntal & Co. analyst David Saks, who issued a note Thursday morning on the company. "I think it's very significant for shareholders of Immune Response," he added. Agouron said the two companies will split all profits from the commercialization of Remune. Under the agreement, Agouron could pay Immune Response up to $77 million over the next two years, including license and milestone payments of $45 million, payments to support development of $18 million, and the purchase of $14 million of Immune Response common stock. Immune Response will receive $10 million of the total up front as a license fee. Agouron said it bought 118,256 newly issued Immune Response common shares for $2 million. Immune Response had been intimating that it was working on getting a collaborator, Saks said. Had he known it was Agouron and been aware of the substantial amount of money involved, he would have increased his price targets in his report, he added. Saks, who rates Immune Response a "strong buy," has a 12-month price target of $19. He expects the stock will open strongly in trading Friday. Immune Response is well along in its development of Remune, which is why Agouron was willing to pay so much, he said. Lehman Brothers analyst Tony Butler said Agouron is an "outstanding partner" for Immune Response. Butler said Immune Response likely won't file the drug until next summer. If the results are favorable, the drug wouldn't be expected on the market until the end of 1999. -Melanie Trottman 201-938-5099 Copyright (c) 1998 Dow Jones & Company, Inc. All Rights Reserved.

To: TokyoMex who wrote (482)	6/12/1998 12:04:00 AM
From: Emec	Respond to of 1510

Short Stories briefing.com Updated: 11-Jun-98 AFTER THE CLOSE****** Owens & Minor Inc. (OMI)11 1/8 +1/8: distributor of finished medical and surgical products is warning that loss of Columbia/HCA contract will impact earnings by $1.5 mln to $2 mln; expects to take a restructuring charge of $7 mln to $8.5 mln in Q2; in late May, company warned that it had lost distribution contract with Columbia/HCA which provided $360 million or about 11% to OMI's annual sales volume; for Q2, OMI was projected to earn $0.19 a share vs year-ago net of $0.14, according to First Call..... Advanced Deposition Technologies (ADTC) 2 7/16 -1/32: developer and maker of standard and proprietary metallized films for energy management applications warns that 1998 revenues to decline by 10% and earnings to be below expectations; cites higher training and staffing costs for miss; there are not estimates for this particular period..... Rogers Corp. (ROG) 33 -1/8: manufacturer and marketer of specialty polymer composite materials and components warns about Asia's impact on Q2 results; sees earnings between $0.30 and $0.32 a share on lower sales; sales projected 10% below Q1 level of $58 mln when it earned $0.56 a share; according to First Call, company expected to earn $0.60 a share vs year-ago profit of $0.52 a share..... Compaq Computer (CPQ) 28 1/16 -5/8: PC maker's CFO warns that company will report slightly disappointing results for Q2 and that Q3 will be a transitional qtr. Puts Q2 net at the breakeven level vs yr-ago earnings of $0.33 and the First Call mean of $0.01. Says sees Digital Equipment merger accretive in Q4. These comments were made on a conference call with analysts.... GenRad Inc. (GEN) 17 1/16 +7/16: supplier of integrated test, measurement and diagnostic solutions plans to reduce its workforce as company cautious about outlook for 1998; sees a Q2 one-time net charge equalling $40 mln for job reduction; company, however, comfortable with full-year estimates of $0.80 to $1.00; according to First Call, GenRad projected to earn $0.24 in Q2 and $0.80 for the full-year; company does plan to buyback as much as 8% of its stock..... TSI Inc. (TSII) 8 1/8 unch: manufacturer of measuring and control instruments for monitoring air quality posts a fiscal Q4 net of $0.16 a share, in line with the First Call estimate, vs year-ago net of $0.13 a share..... Rural/Metro Corp. (RURL) 17 3/8 -1: provider of ambulatory services, fire protection, and home health care services is warning that it sees a fiscal Q4 net of between $0.25 and $0.30 a share, excluding charges and will take a Q4 provision of $0.69 a share for doubtful accounts; according to First Call, RURL was projected to earn $0.48 vs year-ago net of $0.39 a share..... CMG Information Services Inc. (CMGI) 42 11/16 -1 9/16: direct marketing service provider reports a Q3 loss of $0.55 a share, including one-time charges and gains; the First Call estimate called for a loss of $0.61, vs year-ago loss of $0.29 a share; net sales rose 7.5% to $20.43 mln and 14.7% on a sequential basis..... Immune Response Corp. (IMNR) 13 11/16 +1 15/16: biopharmaceutical company inks collaboration deal with Agouron Pharmaceuticals (AGPH 34 -1) for Remune, an immune-based therapy for the treatment of HIV infection; pact is said to be worth $77 mln over two years.....